Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-21-124713
Filing Date
2021-04-21
Accepted
2021-04-21 16:13:59
Documents
14

Document Format Files

Seq Description Document Type Size
1 DEFA14A d173024ddefa14a.htm DEFA14A 69990
2 GRAPHIC g173024g01t58.jpg GRAPHIC 19866
3 GRAPHIC g173024g0415075222909.jpg GRAPHIC 3857
4 GRAPHIC g173024g66n09.jpg GRAPHIC 9524
5 GRAPHIC g173024g96x20.jpg GRAPHIC 1264
6 GRAPHIC g173024snap0003.jpg GRAPHIC 1396
7 GRAPHIC g173024snap0004.jpg GRAPHIC 2099
8 GRAPHIC g173024snap0005.jpg GRAPHIC 1760
9 GRAPHIC g173024snap0006.jpg GRAPHIC 1485
10 GRAPHIC g173024snap0007.jpg GRAPHIC 902
11 GRAPHIC g173024snap0008.jpg GRAPHIC 949
12 GRAPHIC g173024snap3.jpg GRAPHIC 1828
13 GRAPHIC g173024sp7.jpg GRAPHIC 53900
14 GRAPHIC g173024spi7.jpg GRAPHIC 13854
  Complete submission text file 0001193125-21-124713.txt   228122
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 5 BAZEL ST PO B 3190 PETACH TIKVA L3 49131
Business Address 5 BAZEL ST P O B 3190 PETACH TIKVA L3 49131 9729267267
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-16174 | Film No.: 21841690
SIC: 2834 Pharmaceutical Preparations